1. Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood–brain barrier disruption: where are we now, and where we are going
   Randy S. D’Amico et al, 2020, Journal of Neuro-Oncology CrossRef
2. AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion
   Jie Zhang et al, 2019, Disease Markers CrossRef
3. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects
   X. Zhu et al, 2021, Cancer Chemotherapy and Pharmacology CrossRef
4. Novel Strategies Using Sagacious Targeting for Site-Specific Drug Delivery in Breast Cancer Treatment: Clinical Potential and Applications
   Pedram Ebrahimnejad et al, 2024, Critical Reviews™ in Therapeutic Drug Carrier Systems CrossRef
5. HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
   Luying Xu et al, 2024, Frontiers in Pharmacology CrossRef
6. Neratinib for HER2-positive breast cancer with an overlooked option
   Liting Guo et al, 2023, Molecular Medicine CrossRef
7. Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
   Agampodi Danushi Mendis Gunasekara et al, 2024, Scientific Reports CrossRef
8. Identification of Lapatinib Derivatives and Analogs to Control Metastatic Breast Cancer-specific to South Asian Population-a Pharmacogenomic Approach
   Hima Vyshnavi A M et al, 2021, WSEAS TRANSACTIONS ON BIOLOGY AND BIOMEDICINE CrossRef